What drug is enasidenib? What are the indications?

Enasidenib is a targeted therapy drug mainly used to treat specific types of hematological malignancies. It is an oral small molecule drug that exerts therapeutic effects by inhibiting the activity of mutations in IDH2 (isocitrate dehydrogenase 2). IDH2mutations are common in certain types of leukemia, especially acute myeloid leukemia (AML). Ensidipine's targeting mechanism makes it an effective option for treating leukemias associated with these specific genetic mutations.

The main indication of ensidipine is the treatment of patients with acute myeloid leukemia (AML), especially those carrying IDH2 mutations. AML is a rapidly developing blood cancer in which patients produce large numbers of abnormal white blood cells in their bone marrow and blood. IDH2 mutation is a common gene mutation in AML. By targeting this mutation, ensidipine can effectively inhibit the proliferation of cancer cells and improve patients' survival rate and treatment response. Therefore, ensidipine is mainly used as an adjuvant treatment option for those patients with AML mutations in IDH2.

Ensidipine is usually used in patients with AML who have relapsed or become resistant to other treatments (such as chemotherapy). There are relatively few treatment options for these patients, and ensidipine as a targeted drug provides a new treatment approach for these patients. Its advantage is that it can specifically act on IDH2 mutations, causing less damage to normal cells, thereby reducing side effects and toxicity, and providing a more precise and personalized treatment plan.

In general, ensidipine, as a targeted drug, provides new hope for the treatment ofAML. By precisely acting on IDH2 mutations, it can effectively improve the treatment effect of patients, especially suitable for those AML patients with IDH2 mutations. With further clinical research and application, ensidipine is expected to play a greater role in the treatment of hematological diseases and become one of the new standards in the treatment of AML.

Reference materials:https://www.idhifa.com/